CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria-based therapeutics, an emerging class of drugs with the potential to treat a range of chronic and age-related diseases. Co.'s efforts focus on the development of these peptides into therapeutics that provide the potential to address a range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases including idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS) including COVID-19 associated ARDS, cancer, type 2 diabetes, cardiovascular and neurodegenerative diseases. Co.'s key compound, CB4211, is in clinical trial for NASH and obesity. The CWBR stock yearly return is shown above.
The yearly return on the CWBR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CWBR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|